
Government Proposes Cap on Expensive Cancer Drug Trade Margins to Lower Retail Costs
The Department of Pharmaceuticals approved a decisive trade margin rationalization (TMR) policy, capping profit margins on non-scheduled anti-cancer drugs at 30% of their Maximum Retail Price (MRP). Expected to lower the retail costs of roughly 110 oncology m…








